JERUSALEM, May 12, 2022
/PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq:
BVXV), a biopharmaceutical company focused on developing,
manufacturing and commercializing innovative products for the
prevention and treatment of infectious diseases and other
illnesses, announced that Dr. Tamar
Ben-Yedidia, BiondVax's Chief Scientific Officer, today
presented BiondVax's progress, achieving certain milestones, under
its nanosized antibodies (NanoAbs) program.
Dr. Ben Yedidia today presented
at the Biomed conference in Tel Aviv,
Israel and the associated presentation will be accessible
from the Company's investor relations website. The main highlights
of the progress are summarized below.
The NanoAb program, in collaboration with the Max Planck
Institute for Multidisciplinary Sciences and University Medical
Center Göttingen, Germany, aims to
address diseases with large unmet medical needs and attractive
commercial opportunities, such as COVID-19, asthma, psoriasis,
psoriatic arthritis, and macular degeneration.
Summary of Recent Achievements
- Successful technology transfer from Max Planck to BiondVax'
manufacturing facility in Jerusalem was demonstrated. Upon testing,
it was shown that BiondVax was able to successfully manufacture its
first exclusively licensed NanoAb for the treatment of COVID-19 and
demonstrated strong in-vitro COVID-19 neutralization capability at
levels similar to those demonstrated by NanoAbs originally produced
at Max Planck.
- Those NanoAbs produced at BiondVax's facility demonstrated
similarly strong COVID-19 in-vitro neutralization capacity also
after being sprayed through a medical device inhaler that is
expected to be used in the first in-human clinical trials planned
for 2023.
- A new NanoAb targeting Omicron, that was generated by Max
Planck, has recently been shown to successfully neutralize the
Omicron variant of COVID-19, in-vitro. This NanoAb is expected
to be manufactured and used in BiondVax's first in-human
trials.
Amir Reichman, CEO of
BiondVax, added, "I am very pleased with the solid progress we
have made in recent months. Demonstrating our ability to
successfully take a drug candidate from an academic setting,
develop a manufacturing process that follows industrial
pharmaceutical principals for quality and analytics, while keeping
the targeted drug viral neutralization capacity, is a testimony to
BiondVax's competencies. In addition, as NanoAbs are in-fact a
platform, those achievements will be leveraged towards our next
in-line NanoAbs, which we expect to receive from our partners at
Max Planck and UMG. I am very excited with the potential inherent
to our NanoAb program."
About BiondVax
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a
biopharmaceutical company focused on developing, manufacturing and
commercializing innovative products for the prevention and
treatment of infectious diseases and other illnesses. Since its
inception, the company has executed eight clinical trials including
a seven country, 12,400 participant Phase 3 trial of its vaccine
candidate and has built a state-of-the-art manufacturing facility
for biopharmaceutical products. With highly experienced
pharmaceutical industry leadership, BiondVax is aiming to develop a
pipeline of diversified and commercially viable products and
platforms beginning with an innovative nanosized antibody (NanoAb)
pipeline. For more information, please visit www.biondvax.com.
Contact Details
Company: Joshua E. Phillipson |
+972 8 930 2529 | j.phillipson@biondvax.com
Investor Relations: Kenny Green | +1
212 378 8040 | kgreen@edisongroup.com
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, prospects, plans and objectives
of management are forward-looking statements. Examples of such
statements include, but are not limited to, statements regarding
the therapeutic and commercial potential of NanoAbs . These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include,
but are not limited to, the risk that the therapeutic and
commercial potential of NanoAbs will not be met; the risk of a
delay in the preclinical and clinical data for NanoAbs, if any; the
risk that BiondVax and EIB will not reach agreement with respect to
the restructuring of the loan from European Investment Bank; the
risk that BiondVax may not be able to secure additional capital on
attractive terms, if at all; the risk that the European Investment
Bank may accelerate the loans under its finance contract with
BiondVax; risks relating to the COVID-19 (coronavirus) pandemic;
BiondVax's ability to acquire rights to additional product
opportunities; BiondVax's ability to enter into collaborations on
terms acceptable to BiondVax or at all; timing of receipt of
regulatory approval of BiondVax's manufacturing facility in
Jerusalem, if at all or when
required; the risk that the manufacturing facility will not be able
to be used for a wide variety of applications and other vaccine and
treatment technologies, and the risk that drug development involves
a lengthy and expensive process with uncertain outcomes. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in the
Company's Annual Report on Form 20-F filed with the Securities and
Exchange Commission on March 28,
2022. BiondVax undertakes no obligation to revise or update
any forward-looking statement for any reason.
Logo -
https://mma.prnewswire.com/media/615570/BiondVax_Pharmaceuticals_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/biondvax-provides-update-at-biomed-israel-conference-and-announces-significant-progress-in-its-nanosized-antibodies-program-301545874.html
SOURCE BiondVax Pharmaceuticals Ltd.